VANCOMYCIN
PeakNDAINTRAVENOUS, ORALSOLUTIONPriority Review
Approved
Aug 2021
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
4/8 — Partial
Priority Review
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Vancomycin is a glycopeptide antibiotic administered intravenously or orally that works by inhibiting bacterial cell-wall biosynthesis and altering cell-membrane permeability. It is the gold-standard treatment for serious gram-positive infections, particularly methicillin-resistant Staphylococcus aureus (MRSA), and has broad utility across hospital-acquired infections, endocarditis, and Clostridioides difficile colitis. The drug has been in use for decades and represents a foundational therapy across infectious disease, critical care, and surgical prophylaxis.
$30KPart D
PeakStable
9.5 years to LOEVancomycin is a stable, mature product with minimal Part D exposure, indicating strong hospital and institutional purchasing; team size likely focused on maintaining market position rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
STOP-CDI: Efficacy of Fecal Microbiota Transplantation vs Fidaxomicin vs Vancomycin in Treating and Preventing Relapse of Clostridioides Difficile Infection
Started Oct 2025
424 enrolled
Clostridioides Difficile InfectionClostridioides Difficile Infection RecurrenceFecal Microbiota Transplantation (FMT)+3 more
A Model for Drug Concentration Prediction of Vancomycin
Started Mar 2024
401 enrolled
Critical IllnessInfectionsDrug Use
Continuous vs. Intermittent Infusion Vancomycin
Started May 2023
37 enrolled
Vancomycin
Optimizing Vancomycin Therapy in Children
Started Dec 2022
29 enrolled
SepsisCritical IllnessInfections+1 more
Clinical Decision Support Tool for Vancomycin Dosing in Children
Started May 2022
75 enrolled
Gram-Positive Bacterial InfectionsVancomycinPharmacokinetics+1 more
Worked on VANCOMYCIN at Hikma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.